Biogen Inc. $BIIB Stock: Mather Group LLC. Increases Stake

Mather Group LLC. boosted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 2,194.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 36,433 shares of the biotechnology company’s stock after purchasing an additional 34,845 shares during the quarter. Mather Group LLC.’s holdings in Biogen were worth $8,229,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BIIB. BlackRock Inc. acquired a new position in shares of Biogen during the second quarter worth approximately $3,453,878,000. Primecap Management Co. CA bought a new stake in shares of Biogen in the second quarter valued at approximately $3,274,304,000. Legal & General Group Plc bought a new stake in shares of Biogen in the second quarter valued at approximately $322,640,000. Bank of America Corp DE bought a new stake in shares of Biogen in the second quarter valued at approximately $241,172,000. Finally, Deutsche Bank AG acquired a new stake in shares of Biogen in the second quarter worth $193,165,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Price Performance

Shares of BIIB stock opened at $232.83 on Thursday. The stock has a 50 day moving average of $218.89 and a two-hundred day moving average of $203.29. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. Biogen Inc. has a 12 month low of $138.00 and a 12 month high of $238.24. The company has a market capitalization of $34.40 billion, a P/E ratio of 41.21, a P/E/G ratio of 2.53 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. The business had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%. Biogen’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the business posted $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities analysts expect that Biogen Inc. will post 12.41 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on BIIB shares. Wolfe Research raised shares of Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 target price on the stock in a research report on Thursday, August 13th. BMO Capital Markets reiterated a “market perform” rating and set a $220.00 target price on shares of Biogen in a research note on Monday. Wall Street Zen cut shares of Biogen from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Oppenheimer reissued an “outperform” rating and issued a $300.00 price target on shares of Biogen in a report on Wednesday, July 29th. Finally, HSBC increased their price target on shares of Biogen from $165.00 to $175.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $236.04.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.